Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • DNase Platform
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • DNase
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Financials
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Proxy Materials
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia

Sep 16, 2015

Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out

Sep 9, 2015

Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels

Sep 2, 2015

Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia

Jul 14, 2015

Xenetic Biosciences Completes $3,000,000 Bridge Note Financing

Jul 8, 2015

Xenetic Biosciences Announces Board Change

Apr 21, 2015

Xenetic Biosciences to Hold Business Update Conference Call January 20th

Jan 16, 2015

Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time

Dec 19, 2014

Xenetic Biosciences CEO Delivers “2014 – The Year in Review” Update to Investors and Stakeholders

Dec 18, 2014

Xenetic Biosciences Announces OncoHist™ Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting

Dec 4, 2014

RSS
  • « Previous
  • 1...
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2022Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap